The tumor suppressor protein p53 is widely implicated in cancer. MDM2, a regulator of cell growth, can inhibit p53 and MDM2-A is one MDM2 splice isoform that is often detected in tumors. Here, Erin Volk, Katja Schuster and colleagues study the role of this truncated protein by creating trans- genic mice that express MDM2-A in normal tissues. Although the mice were not prone to tumor development, heterozygote mice had a shorter life span than wild-type mice and homozygotes died shortly after birth. Studies using MDM2-A mice showed that, in contrast to the cancer-promoting activity of full-length MDM2 protein, MDM2-A activates p53, inhibits growth and enhances cell senescence. This work encourages further exploration of the unique roles of MDM2 variants in tumori-genesis and cell growth.
MDM2 variant found in tumors paradoxically promotes cell death
MDM2 variant found in tumors paradoxically promotes cell death. Dis Model Mech 7 January 2009; 2 (1-2): 1. doi:
Download citation file:
Advertisement
Cited by
DMM Journal Meeting 2024: Pre-clinical Modelling of Human Genetic Disease and Therapy

Registration is now open for our 2024 Journal Meeting. Rapid advances in gene editing and genetic technologies have revolutionised our ability to model human genetic disease and provided new hope for gene therapies. At this Meeting, we will present the very latest advances in modelling human genetic disease.
Moving towards heart success – Disease Models & Mechanisms Special Issue

DMM's most recent special issue compiles articles that aim to move heart failure to heart success by fundamentally addressing the roots of failure to identify curative strategies.
Crossroads in Virology

Our October Editorial written by Sumana Sanyal emphasises the urgency of a concerted effort in understanding virus–host interactions to inform the development of therapeutics and vaccines, helping to predict disease outcomes. Read the full Editorial here.
A Model for Life - an interview with Professor Kiran Musunuru




Read our new A Model for Life interview with Kiran Musunuru. Prof Musunuru investigates the mechanisms of disease in model systems, with the ultimate goal of developing innovative gene editing therapies.
Sustainable Conferencing Initiative

Through our Sustainable Conferencing Grants, we promote the use of new technology and greener modes of travel. Our blog posts showcase examples of sustainability in action and share experience about how new technologies and conference formats work in practice.
Other journals from
The Company of Biologists